# US 2012/0251577 A1 · Selectively disrupted whole-cell vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251577 A1
- Document ID: US20120251577A1
- Status: Published application
- Kind: A1
- Application number: 13/500,925
- Filed: 2010-10-12
- Published: 2012-10-04
- Earliest claimed: 2009-10-09
- Assignees: Children's Medical Center Corporation; FundaçãO Butantan; Path Vaccine Solutions
- Inventors: Richard Malley; Porter Anderson; Yingjie Lu; George A. Robertson; Mark Alderson; Jean-Francois Lucien Maisonneuve; Andrea Maria Tate; Waldely de Oliveira Dias; Viviane Maimoni Gonçalves
- Web page: https://patentgrep.com/patent/US20120251577A1

## CPC

- A61K 39/092: {Streptococcus}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/543: {intranasal}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55544: {Bacterial toxins}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides for immunogenic compositions and methods for producing an immunogenic composition with multiple immunity-inducing fractions of killed, whole-cell Streptococcus pneumoniae by selectively disrupting a whole cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the immunogenic composition.

## Claims

### Claim 1

An immunogenic composition with multiple immunity inducing fractions of whole-cell gram positive bacteria, prepared by selectively disrupting a whole-cell bacterial preparation in such a manner that a soluble fraction that induces a primarily antibody response, and a cellular fraction that induces a primarily antibody-independent response, remain in the composition.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1 wherein said bacteria is unencapsulated.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein said bacteria is Streptococcus pneumoniae.

### Claim 4 (depends on 1)

The immunogenic composition of claim 1, wherein said selective disruption is effected by a chemical.

### Claim 5 (depends on 4)

The immunogenic composition of claim 4, wherein said chemical is chloroform, trichloroethylene, or beta-propiolactone.

### Claim 6 (depends on 1)

The immunogenic composition of claim 1, wherein said selective disruption is effected by sonication.

### Claim 7 (depends on 1)

A vaccine comprising the immunogenic composition of claim 1.

### Claim 8 (depends on 7)

The vaccine of claim 7, wherein said vaccine includes an adjuvant.

### Claim 9 (depends on 7)

The vaccine of claim 7, wherein said vaccine is formulated for nasal, buccal, transdermal, subcutaneous, or intramuscular administration.

### Claim 10 (depends on 7)

A method for inducing an immune response in a mammal comprising administering the vaccine of claim 7.

### Claim 11

A method for producing a killed, whole-cell immunogenic composition with antibody-dependent and antibody-independent immunity inducing fractions of bacteria derived from a gram positive bacterium comprising selectively disrupting the bacteria in such a manner that a soluble fraction and a disrupted cellular fraction remain in the whole-cell immunogenic composition.

### Claim 12 (depends on 11)

The method according to claim 11, wherein said bacteria is unencapsulated.

### Claim 13 (depends on 11)

The method of claim 11, wherein said bacteria is Streptococcus pneumoniae.

### Claim 14 (depends on 11)

The method according to claim 11, wherein said soluble fraction induces a serotype-independent antibody response, and said cellular fraction induces increased phagocytosis.

### Claim 15 (depends on 11)

The method according to claim 11, wherein disrupting the bacteria is effected by a chemical.

### Claim 16 (depends on 15)

The method according to claim 15, wherein said chemical is beta-propriolactone, chloroform, or trichloroethylene.

### Claim 17 (depends on 15)

The method according to claim 15, further comprising negating the chemical in such a manner that preserves said soluble fraction and said cellular fraction.

### Claim 18 (depends on 11)

The method of claim 11, wherein disrupting the bacteria is effected by sonication.
